WallStreetZenWallStreetZen

NASDAQ: OCX
Oncocyte Corp Stock

$3.84+0.02 (+0.52%)
Updated Dec 7, 2023
OCX Price
$3.84
Fair Value Price
$3.94
Market Cap
$31.72M
52 Week Low
$2.08
52 Week High
$10.00
P/E
-0.41x
P/B
0.84x
P/S
-10.91x
PEG
N/A
Dividend Yield
N/A
Revenue
-$2.36M
Earnings
-$57.40M
Gross Margin
-107.3%
Operating Margin
2,435.37%
Profit Margin
2,462.4%
Debt to Equity
1.04
Operating Cash Flow
-$28M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

OCX Overview

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OCX ($3.84) is undervalued by 2.51% relative to our estimate of its Fair Value price of $3.94 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
OCX ($3.84) is not significantly undervalued (2.51%) relative to our estimate of its Fair Value price of $3.94 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OCX due diligence checks available for Premium users.

Be the first to know about important OCX news, forecast changes, insider trades & much more!

OCX News

Valuation

OCX fair value

Fair Value of OCX stock based on Discounted Cash Flow (DCF)
Price
$3.84
Fair Value
$3.94
Undervalued by
2.51%
OCX ($3.84) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OCX ($3.84) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OCX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

OCX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.41x
Industry
31.65x
Market
31.17x

OCX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
3.95x
OCX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

OCX's financial health

Profit margin

Revenue
$429.0k
Net Income
-$6.5M
Profit Margin
-1,558.7%
OCX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OCX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$81.6M
Liabilities
$39.1M
Debt to equity
1.04
OCX's short-term assets ($16.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCX's long-term liabilities ($31.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OCX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.3M
Investing
-$1.3M
Financing
-$30.0k
OCX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

OCX vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
OCX$31.72M+0.66%-0.41x0.84x
LMDX$32.21M-8.18%-0.09x-0.15x
CNTG$34.49M-1.57%-0.79x-2.08x
XGN$28.13M-2.65%-0.89x1.02x
AWH$39.07M+12.84%-1.52x-59.29x

Oncocyte Stock FAQ

What is Oncocyte's quote symbol?

(NASDAQ: OCX) Oncocyte trades on the NASDAQ under the ticker symbol OCX. Oncocyte stock quotes can also be displayed as NASDAQ: OCX.

If you're new to stock investing, here's how to buy Oncocyte stock.

What is the 52 week high and low for Oncocyte (NASDAQ: OCX)?

(NASDAQ: OCX) Oncocyte's 52-week high was $10.00, and its 52-week low was $2.08. It is currently -61.6% from its 52-week high and 84.62% from its 52-week low.

How much is Oncocyte stock worth today?

(NASDAQ: OCX) Oncocyte currently has 8,260,762 outstanding shares. With Oncocyte stock trading at $3.84 per share, the total value of Oncocyte stock (market capitalization) is $31.72M.

Oncocyte stock was originally listed at a price of $180.00 in Jan 4, 2016. If you had invested in Oncocyte stock at $180.00, your return over the last 7 years would have been -97.87%, for an annualized return of -42.28% (not including any dividends or dividend reinvestments).

How much is Oncocyte's stock price per share?

(NASDAQ: OCX) Oncocyte stock price per share is $3.84 today (as of Dec 7, 2023).

What is Oncocyte's Market Cap?

(NASDAQ: OCX) Oncocyte's market cap is $31.72M, as of Dec 8, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Oncocyte's market cap is calculated by multiplying OCX's current stock price of $3.84 by OCX's total outstanding shares of 8,260,762.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.